Synthetic Human Secretin

PreclinicalSmall molecule

MMayo Clinic

Synthetic Human Secretin is one of 46 small molecule programs targeting Pancreatic. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PancreaticCompleted

Pancreatic CancerActive, not recruiting

Pancreatic Exocrine InsufficiencyWithdrawn

PancreaticPreclinical

Completed

Pancreatic CancerPreclinical

Active, not recruiting

Pancreatic Exocrine InsufficiencyPreclinical

Withdrawn

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

1 10

PEG-Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pancreatic2 trials

Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients

Completed·EElizabeth Hecht·N/A·NCT01094561·23 enrolled

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

Withdrawn·—·N/A·NCT01094535

Pancreatic Exocrine Insufficiency1 trial

Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency

Withdrawn·—·N/A·NCT01094600

Abdominal pain1 trial

Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency

Terminated·OOrlando Health, Inc.·Phase 3·NCT04231279·27 enrolled

Pancreatic Adenocarcinoma1 trial

Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma

Terminated·MMayo Clinic·Phase 1/2·NCT00587132·4 enrolled

Pancreatic Cancer1 trial

Optical and Biochemical Biomarkers in Early Pancreatic Cancer

Completed·MMayo Clinic··NCT03404661·346 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Synthetic Human Secretin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Synthetic Human Secretin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Synthetic Human Secretin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mayo Clinic company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: MMayo Clinic

Synthetic Human Secretin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pancreatic2 trials

Pancreatic Exocrine Insufficiency1 trial

Abdominal pain1 trial

Pancreatic Adenocarcinoma1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News